EP Patent

EP3842044A1 — Compounds for use in the treatment of brain metastases in a patient with erbb2+ breast cancer

Assigned to Array Biopharma Inc · Expires 2021-06-30 · 5y expired

What this patent protects

A solid dispersion comprising N 4-(4-([1,2,4]triazolo[1,5- a ]pyridin-7-yloxy)-3-methylphenyl)- N 6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and a dispersing polymer, for use in treating brain metastases in a patient having ErbB2 positive breast cancer.

USPTO Abstract

A solid dispersion comprising N 4-(4-([1,2,4]triazolo[1,5- a ]pyridin-7-yloxy)-3-methylphenyl)- N 6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and a dispersing polymer, for use in treating brain metastases in a patient having ErbB2 positive breast cancer.

Drugs covered by this patent

Patent Metadata

Patent number
EP3842044A1
Jurisdiction
EP
Classification
—
Expires
2021-06-30
Drug substance claim
No
Drug product claim
No
Assignee
Array Biopharma Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.